文献速递其他结缔组织病

Blinatumomab治疗难治性系统性硬化症的安全性与疗效:病例系列

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series.
PubMed 文献 · Ann Rheum Dis · 2026-03-06

该探索性病例系列纳入5例抗拓扑异构酶I阳性难治性系统性硬化症患者,接受14天连续静脉输注blinatumomab(前7天9 µg/d,后7天增至28 µg/d)。结果示总体耐受良好,3例出现低级别细胞因子释放综合征,无神经毒性或严重感染;所有患者外周CD19⁺ B细胞快速耗竭,3个月时mRSS中位变化-4分,但3至6个月间全部临床复发。

要点

  • Blinatumomab可快速耗竭外周CD19⁺ B细胞,3个月时mRSS中位下降4分。
  • 3例发生低级别CRS(1级2例,2级1例),无神经毒性或严重感染。
  • 单周期治疗后3至6个月全部复发,多数需恢复免疫抑制治疗。

核心结论

  • Blinatumomab诱导难治性SSc患者快速B细胞耗竭和短期临床改善,但单周期治疗后疗效缺乏持久性。

研究设计与样本

  • 探索性病例系列,纳入2家三级医院的5例难治性抗拓扑异构酶I阳性SSc患者。
  • Blinatumomab 14天连续静脉输注:前7天9 µg/d,后7天增至28 µg/d。
  • 中位随访8个月(范围6-12个月)。

主要发现

  • 所有患者实现外周CD19⁺ B细胞快速耗竭,除1例外均在1个月内B细胞重建,以naïve和过渡型亚群为主。
  • 3个月时mRSS中位变化-4分(范围+1至-8),基线中位16分(范围0-25),肺功能和患者报告结局呈短暂改善。
  • 所有患者在3至6个月间临床复发,多数恢复免疫抑制治疗。

关键数值与推荐

  • 安全性评估包括细胞因子释放综合征(CRS)、神经毒性、感染和血清免疫球蛋白水平。
  • 3例发生低级别CRS(1级n=2,2级n=1),保守处理;无神经毒性或严重感染。
  • 探索性疗效指标包括改良Rodnan皮肤评分(mRSS)、肺功能检查和患者报告结局。
  • 免疫学终点包括外周CD19⁺ B细胞计数、B细胞亚群表型和6基因I型干扰素特征。

临床怎么用

  • Blinatumomab单周期方案在难治性SSc中显示短期B细胞耗竭和临床改善,但需关注3至6个月内的复发并计划后续免疫抑制治疗。
  • 治疗期间需监测CRS、神经毒性、感染和免疫球蛋白水平。

局限性

  • 探索性病例系列,样本量仅5例,无对照组。
  • 随访中位8个月(范围6-12个月),不足以评估长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to evaluate the safety, biological activity, and exploratory clinical effects of CD19-directed T-cell engagement with blinatumomab in patients with severe, treatment-refractory antitopoisomerase I-positive systemic sclerosis (SSc). METHODS: We conducted an exploratory case series of 5 patients with refractory SSc who received a 14-day continuous intravenous infusion of blinatumomab (9 µg/d for 7 days, escalated to 28 µg/d for 7 days) in 2 tertiary hospitals. Safety assessments included cytokine release syndrome (CRS), neurotoxicity, infections, and serum immunoglobulin levels. Exploratory efficacy outcomes comprised modified Rodnan skin score (mRSS), pulmonary function tests, and patient-reported outcomes. Immunologic endpoints included serial peripheral CD19⁺ B-cell counts, B-cell subset phenotyping, and a 6-gene type I interferon signature. Patients' follow-up was a median of 8 months (range: 6-12). RESULTS: Blinatumomab administration was generally well tolerated. Three patients experienced low-grade CRS (grade 1, n = 2; grade 2, n = 1), managed conservatively; no neurotoxicity or severe infections occurred. Rapid peripheral CD19⁺ B-cell depletion was achieved in all patients. B-cell repopulation occurred by 1 month in all but 1 patient and was dominated by naïve and transitional subsets. At 3 months, modest clinical improvements were observed, including a median mRSS change of -4 points (range: +1 to -8) from a baseline of 16 (range: 0-25) and a transient improvement in lung function and patient-reported outcomes. However, all patients experienced clinical relapse between months 3 and 6, leading to resumption of immunosuppressive therapy in most cases. CONCLUSIONS: CD19-directed T-cell engagement with blinatumomab induces rapid B-cell depletion and short-term clinical improvement in refractory SSc but lacks durability after a single treatment cycle.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Scherlinger M, Dieudonné Y, Hilliquin S, et al. Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series. Ann Rheum Dis. 2026. PMID: 41792022. doi:10.1016/j.ard.2026.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。